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loss by 94, 76 and 87% respectively. The cost per case avoided would be 165 Euros, 
and cost per hospitalization avoided would be 1,639 Euros with implementation of 
universal vaccination. The cost per QALY saved would be 29,452 Euros and 20,453 
Euros from the health care and societal perspectives respectively. ConClusions: 
RV5 is projected to avert substantial number of RGE hospitalizations and office vis-
its in Slovenia and would be considered a cost effective intervention. KEYWORDS: 
rotavirus vaccine, cost effectiveness, QALY.
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HealtH economIc model on tHe costs and effects of RotavIRus 
vaccInatIon In RomanIa
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objeCtives: Rotavirus gastroenteritis (RVGE) is one of the most frequent diseases in 
children less than 5 years old. Today, no recommendation for general rotavirus vac-
cination exists in Romania, which leads to a vaccination coverage rate of < 8%. We 
model whether the strategy of “Universal Mass Vaccination” should be cost-effective 
from the Social Health Insurance Fund (SHIF) perspective. Methods: We adapted 
an already published simple model to estimate the cost-effectiveness of rotavirus 
vaccination in Romania. It helps identifying the drivers of the economic analysis in 
a birth cohort of 194,411 children (Romania 2012) followed over a period of 5 years. 
In the model, vaccine efficacy results from international clinical trials are combined 
with Romanian epidemiology and cost data from the SHIF perspective for 2012. The 
model assumes a theoretical vaccination rate of 100% and uses discount rates of 3% 
on costs and effects. Results are tested on their robustness using univariate sensitiv-
ity analysis. Results: The model predicts that a two-dose rotavirus vaccine could 
avoid around 82,581 mild, 51,328 moderate and 3,075 severe RVGE cases. Moderate 
and severe events are associated with physician visits and hospital stays respectively. 
These also lead to a total cost saving of € 2.4 million for indirect cost estimates. 
The main factors responsible for the savings are the reduction in hospital stays, in 
productivity losses of parents and in medical visits. Sensitivity analysis indicates 
the importance of good epidemiological data and cost numbers on productivity 
loss. ConClusions: General vaccination against rotavirus could avoid many of the 
severe diarrhea events in children less than 5 years old in Romania. Depending on the 
price per course, the vaccination strategy will lead to societal cost gain.
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objeCtives: Coffee contains over 1,000 distinct molecular compounds and is one 
of the most widely consumed beverages worldwide. Epidemiologic studies have 
shown an inverse relationship between coffee consumption and all-cause mortal-
ity. This analysis aims to assess the cost-effectiveness of coffee from a blended 
German consumer and payer perspective. Methods: An existing decision-analytic 
model was adapted with German data. A cohort life-table analysis was developed 
to model life-years (LYs) of German coffee consumers vs. non-consumers over a 
lifetime horizon. Age- and gender-specific mortality rates were used to model sur-
vival outcomes. Relative risks of death by average coffee intake (cups/day) were 
obtained from a recent large, prospective cohort study. Cost were considered for 
cost per cup (home prepared and from a national sample of low and high-cost 
vendors) and for health care. Incremental analyses were conducted by cost, sex, 
and level of daily coffee consumption. Deterministic and probabilistic sensitivity 
analysis was performed. Results: Coffee increased undiscounted LYs in 1, 2-3, 
4-5, and 6+ cup/day male (0.65, 1.10, 1.33 and 1.10) and female (0.45, 1.21, 1.51, 1.41) 
consumers, respectively, versus non-consumers. ICERs per undiscounted LY gained 
were € 3,938/ € 7,047/ € 16,271 for males and € 5,514/ € 5,066/ € 13,537 for females, 
respectively, for 1, 2-3, and 4-5 cups/day consumption of home-prepared coffee; 
≥ 6 cups/day was strictly dominated. Consumption of 4-5 cups per day purchased 
from high-cost vendors was not cost-effective (male: € 168,780/ female: € 135,636). 
Results were consistent throughout the sensitivity analyses, whereas coffee effec-
tiveness in preventing death and coffee acquisition cost has the largest impact on 
ICERs. ConClusions: In this analysis, coffee consumption was associated with 
increased LYs and was shown to be potentially cost-effective, especially if home-
prepared or purchased from low-cost vendors. Given the observational nature of the 
study data, further research is warranted to validate these findings.
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objeCtives: Maternal and congenital syphilis prevalence rates are currently rapidly 
increasing in Mongolia. On-Site screening and same-day treatment for syphilis 
in pregnancy prevents greater numbers of congenital syphilis and its complica-
tions. The Ministry of Health has been implementing on-site rapid screening test 
(RT) intervention and same day treatment approach for maternal syphilis with 
the contribution of the World Health Organization. Objective of the study was to 
understand the cost- effectiveness (CE) of screening antenatal syphilis using the 
RT strategy, to compare this intervention with RPR testing strategy. And in order to 
estimate CE we found out maternal syphilis prevalence. Methods: Ingredients-
based cost data and epidemiological data were collected retrospectively from the 
pregnancy medical records. Decision analysis was used to estimate the incremental 
CE of on-site PT compared to the current practice, off-site PRP/TPHA. Descriptive 
analysis has done for prevalence of syphilis, and economic analysis has done to 
calculate costs. Stability of cost-effectiveness ratios were evaluated by the univariate 
sensitivity analysis. Results: With antenatal syphilis prevalence of 3.0% (1.46% 
in urban and 5.7% in sub-urban area), the cost effectiveness was US$ 14.60/DALY 
able. Results: The strategy of vaccinating people over 65 yo showed incremen-
tal cost-effectiveness ratios of 41,467€ /QALY gained from a payer perspective and 
40,733€ /QALY from a societal perspective. The analysis by age group showed that 
the ICER is age-dependent, the lowest ICER (30,780€ /QALY in both perspectives) 
having been found in the cohort 70-74 years old. In sensitivity analyses data on 
the duration of PHN, utilities and vaccine efficacy duration showed a major impact 
on the results. ConClusions: Our cost-effectiveness analysis shows that a HZ 
vaccination policy for adults aged ≥ 65 years in Norway could be cost-effective and 
provide substantial public health benefits in the Norwegian health care system.
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objeCtives: To analyze the cost effectiveness of surgical management of stress 
urinary incontinence (SUI) in women with single-incision mini-sling (SIMS) com-
pared with tension-free vaginal obturator (TVT-O) Methods: A cost-effectiveness 
analysis based on the results of interventions performed with TVT-O (2005-2008) 
and SIMS (2008-2011) in women with a diagnosis of SUI was performed. The clini-
cal effectiveness was defined as an objective cure at 12 months (pad-test < 1 g/h). 
A perspective of the hospital payer was adopted; therefore, only direct health care 
costs (diagnostic and surgical procedures, medical devices, medications, hospital 
stay times and staff) were included. CI95% of total cost was estimated by boot-
strapping; later, different sensitivity analyses were conducted Results: Procedures 
were carried out in 81 women (44 in the SIMS group and 37 in the TVT-O). A small 
difference (6.7%) in clinical effectiveness was observed in favour of SIMS, however, 
it was not statistically significant (SIMS: 93.2% and TVT-O: 86.5%). The total annual 
cost per patient with SIS was lower (2,059€ ; CI95%: 1,914-2,285) than with TVT-O 
(2,821€ ; CI95%: 2,661-2,997), showing a statistically significant cost saving of 762€ 
(CI95%: 516-987). In the base case, the probability of SIMS is less costly than TVT-O 
was 100%. The sensitivity analysis showed that the cost determinant was the length 
of the hospital stay, observing that an equivalent cost was only achieved if there 
was no cause for any hospital stay with TVT-O. ConClusions: The use of single-
incision mini-sling is associated with an comparable clinical effectiveness but with 
a 762€ per patient reduction of the average annual cost, compared to tension-free 
vaginal obturator. Therefore, the results suggest that, over a post-operative period 
of twelve months, tension-free tape single-incision mini-sling is a dominant alter-
native to tension-free vaginal obturator because of a lower cost and a comparable 
effectiveness.
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objeCtives: To assess cost, clinical outcomes and cost-effectiveness of different 
types of labor in singleton pregnancies. Methods: A decision model was used 
to compare vaginal labor, induced labor and planned cesarean section. All data 
were taken from the Book of Labor from the University Hospital for Gynecology 
and Obstetrics “Narodni Front” in Serbia, for labors conducted during one month 
period in 2011. Successful delivery, (i. e. labor that began up to 42 gestation weeks, 
without maternal mortality and the newborn Apgar scores greater than or equal 
to seven in the first and fifth minute of life) was considered as the outcome of the 
cost effectiveness analysis. To test the robustness of this definition probabilistic 
sensitivity analysis was performed. Results: From a total of 667 births, vaginal 
labor was conducted in 98 cases, induced vaginal in 442, while planned caesarean 
section was performed 127 times. Emergency caesarean section as a complication 
was much higher in the vaginal labor cohort compared to the induced vaginal 
cohort (OR = 17.374, 95% CI: 8.522 to 35.418, p < 0.001). The least costly type of labor 
was induced vaginal labor: average cost 461 euro, with an effectiveness of 98.17%. 
Both, vaginal and planned cesarean labor, were dominated by the induced labor. 
The results were robust. ConClusions: Elective induction of labor was associated 
with the lowest cost compared to other types of labor, with favorable maternal and 
neonatal outcomes.
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objeCtives: To assess the potential impact of universal vaccination with RV5 on 
health care burden and costs associated with rotavirus gastroenteritis (RGE) among 
a hypothetical birth cohort of 21,938 Slovenian children in their first five years of 
life Methods: A Markov model was used to evaluate the cost per quality-adjusted-
life-year (QALY) and public health impact of vaccination with RV5 from the health 
care payer and societal perspectives. The base case assumes three dose coverage 
rate of 94% at 2, 4 and 6 months among the vaccinated, the remaining receiving 1 
or 2 doses. In the absence of universal vaccination 819 hospitalizations and 3,276 
office visits were projected to occur in the first 5 years of life. RGE associated costs 
include direct and indirect costs associated with parental work loss. The efficacy 
of RV5 in reducing health care resource utilization is based on the results of the 
Rotavirus Efficacy and Safety Trial (REST). Results: A universal RV5 vaccination 
program is projected to reduce hospitalizations, office visits and parental work 
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ing an additional unintended pregnancy with ulipristal acetate as compared to 
levonorgestrel is estimated to be 418€ . Ulipristal acetate is most cost-effective in 
the subgroup of intake within 24 hours, where it is more efficacious at a lower cost 
compared to levonorgestrel. ConClusions: Ulipristal acetate is a cost-effective 
alternative to levonorgestrel, given that the cost of avoiding an additional pregnancy 
with ulipristal acetate is less than the average cost of said pregnancies. Therefore, 
French minors should have free access to ulipristal acetate directly in a pharmacy. 
Ulipristal acetate should be used rapidly after unprotected intercourse (within 
24hours) to benefit from its cost-saving potential compared to levonorgestrel use.
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ceRvIcal assessment WItH PRoGesteRone In tHe PReventIon of 
PReteRm bIRtH: a stRateGy based on cost-effectIveness
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intRoduCtion: Preterm birth (PTB) complications are estimated to be the second 
most common cause of death in under-five children and responsible for 3.1million 
neonatal deaths. According to a worldwide analysis, Brazil is one of the top ten 
countries with the highest number of PTB. Considering its long-term costs, strate-
gies that reduce incidence may be cost-effective. Treatment with progesterone is 
one of the interventions recommended for PTB prevention due to the evidence 
supporting its efficacy in women with short cervix and prior history of preterm 
delivery. objeCtives: Determine whether treatment with progesterone for preg-
nant women with a short cervical length < 25mm identified in routine measurement 
of second-trimester transvaginal cervical length by ultrasound in low-risk singleton 
pregnancies is a cost-effective strategy under the Brazilian Healthcare System per-
spective. Methods: A cohort model was developed according to the disease and 
resources use. Epidemiology of pregnancies at risk of PTB eligible for progesterone 
treatment were obtained from published data. To obtain national clinical data, births 
were categorized by gestational week age at delivery specialist opinion. Progesterone 
effectiveness data were obtained from systematic reviews, meta-analysis and spe-
cialist opinion. Costs included screening test, prenatal consultation, progesterone 
and neonatal hospitalization. Exchange rate was 1USD= 2.30BRL. Results were pre-
sented in cost/PTB avoided. Results: Considering 278.100 PTB, the inclusion of 
screening test to identify pregnant women with short cervix and its prophylaxis 
with progesterone shows significant economic savings of USD74 million. Although 
the expenditure on drug, screening test and prenatal consultation increment the 
total costs, the reduced number of PTB (263,052 vs 278.100) and neonatal UTI hos-
pitalization length (4,098,543 days vs 4,518,056 days) resulted in a total economic 
saving. ConClusions: Prevention of PTB is dominant in women with short cervix 
as compared to a no-prophylactic strategy scenario resulting in economic savings 
to the Brazilian health care system.
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cost-effectIveness of PalIvIzumab use In HIGH RIsk cHIldRen fRom 
bRazIlIan HealtH system PeRsPectIve
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objeCtives: This study aimed to investigate the cost-effectiveness of palivizumab 
to different combinations of risk groups, such as premature children born with ges-
tational age (GA) ≤ 28 weeks, GA ≤ 32 weeks, children with congenital heart disease 
and bronchopulmonary dysplasia. Methods: Literature review was performed to 
search effectiveness data. One Markov model (base case), and one decision tree 
(alternative scenario) were built with a cohort simulation along a 18 years-time 
horizon for the base case and a 1 year time horizon for the decision tree. Base case 
consider sequelae after infection, and alternative scenario not. The Health System 
perspective was used, with a discount rate of 5%. A probabilistic sensitivity analysis 
(Monte Carlo simulation) with probability distributions fitted to the variables, was 
performed under the different structural assumptions, as well as a deterministic 
analysis, using Tornado diagram, to verify the variable modifications able to alter 
the responses of the model. A threshold analysis was used to estimate the price 
that palivizumab would fit under an acceptability threshold proposed for the health 
system. Results: The option of using the prophylaxis just in preterm children born 
with GA ≤ 32 weeks dominated all others. The incremental effectiveness of base 
case analysis compared with no prophylaxis (base line) was 0.19 QALY. However, 
this strategy was not cost-effective, presenting an incremental cost-effectiveness 
ratio (ICER) of R$ 81,627.31/QALY, value above of World Health Organization (WHO) 
proposed threshold of three times GDP per capita (R$ 63,756.00/QALY). The ICER of 
GA ≤ 32 weeks in alternative scenario was 2.023.045,72, showing the importance of 
considering sequelae in analysis. Sensitivity analysis showed that some variables 
when altered were able to change model final answers. ConClusions: Threshold 
analyses demonstrated that palivizumab price must be reduced in at least 22% to 
be incorporated to all populations use, based on WHO threshold.
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objeCtives: Children undergoing cardiac surgery for congenital heart disease are 
more likely to experience development of acute kidney injury (AKI) in the immedi-
ate postoperative period. In current clinical practice, AKI diagnosis is based on a 
rise in serum creatinine (sCr) levels, which occurs 2-3 days after the initiating renal 
insult. Many new biomarkers offer promise for earlier AKI diagnosis. The objective 
for RT intervention and US$ 17.88/DALY for RPR intervention. Cost-effectiveness 
ratios (CERs) were more sensitive to the prevalence rate, sensitivity of tests, and 
DALY discount rate. ConClusions: Using the on-site antenatal rapid testing, same 
day treatment for positive results, and confirmed by RPR testing approach is cost-
effective in Mongolia.
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objeCtives: To estimate the cost-effectiveness of the supply of calcium of 1200mg 
per day from the week 14 of pregnancy to all pregnant women compared to not 
supplying it to reduce the incidence of preeclampsia. Methods: A decision tree 
was built in TreeAge® with outcome measured in life years gained (LYG) associated 
to the reduction in maternal deaths. The costs were included from the perspective 
of the Health System in Colombia. Pharmaceutical costs were obtained from 2008 
SISMED (1) and the value of the procedures was calculated by adjusting the values 
of Tariff Manual ISS 2001 + 30% (2), these values were compared with information 
of costs supplied by three EPS. All costs are expressed in Colombian pesos of 2010. 
The discount rate was 0%. It was performed sensitivity univariate and probabilistic 
analyzes for costs and effectiveness. Results: Compared to no intervention, calcium 
supplement is a dominant alternative. If the incidence of preeclampsia is lower than 
51.7 per 1000 pregnant women or the cost per tablet of calcium of 600 mg is greater 
than $454, calcium supplement is no longer a cost-effective alternative in Colombia 
for a threshold of 3 times the GDP per capita in Colombia of 2010 by LYG, equal to 
$36,143,550. ConClusions: Supply of calcium to all pregnant women from week 
14 of gestation is a dominant alternative compared to no intervention, which saves 
200 LYG, while it decreases costs in the order of $5,304 million pesos per 100.000 
pregnant women.
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objeCtives: Ulipristal acetate is a selective progesterone receptor modulator 
that has been demonstrated to be an effective 3-month pre-operative treatment 
for moderate to severe symptoms of uterine fibroids in adult women of repro-
ductive age. The aim of this analysis was to assess the cost-effectiveness of 5 mg 
ulipristal acetate as an add-on therapy to standard pre-surgical observation and 
treatment or immediate hysterectomy in Romania. Methods: A Markov model 
was developed using a 10-year time horizon. Ulipristal acetate was compared with 
pre-surgical observation and immediate hysterectomy. The model comprised the 
following mutually exclusive health states: mild, moderate, severe, or persistent 
severe excessive bleeding disorder; myomectomy; post-myomectomy with mildly to 
moderately excessive bleeding disorder; post-myomectomy with severely excessive 
bleeding disorder; hysterectomy; post-hysterectomy; post-menopause; and death. 
Transition probabilities and utility values were obtained from clinical trials and the 
scientific literature. Resource utilisation and unit costs were derived from the con-
sensus panel of clinical experts and the Romanian National Insurance House tariffs. 
Cost vectors in RON were converted to EUR by using 2013 Romanian National Bank 
average exchange rate (1 EUR = 4.419 RON). Results: Adding a 3-month course of 
ulipristal acetate to pre-operative observation was predicted to achieve an addi-
tional 0.021 quality-adjusted life years (QALYs) at an estimated incremental cost of 
367 € , which would result in an incremental cost of 17,749 € /QALY. When 3 months 
of ulipristal acetate therapy was compared with immediate hysterectomy, the incre-
mental cost-effectiveness ratio was reduced to 2,300 € /QALY. The results were most 
sensitive to the utility value of the post-hysterectomy health state but responsive 
to changes in other model parameters. ConClusions: The results of this analysis 
suggest that adding ulipristal acetate treatment to standard pre-surgical therapy 
represents a good value for money in Romania. The inclusion of societal benefits 
may considerably reduce the cost-effectiveness ratio.
PIH34
tHe cost-effectIveness of emeRGency HoRmonal contRacePtIon 
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objeCtives: To compare the cost and effectiveness of two emergency contracep-
tive methods in minors in France and to support the payer’s analysis if it is worth 
to deliver ulipristal acetate for free to minors. Methods: Based on a decision-
analytical model, the cost-effectiveness of two emergency contraceptive meth-
ods is compared. Pregnancy rates, outcome of unintended pregnancy in minors 
and resource utilization are derived from literature. Resources and their costs are 
considered until termination or a few days after delivery. Costs are taken from a col-
lective perspective. Sensitivity analyses are performed on the most sensitive input 
parameters. Results: Using emergency contraception is superior to no method. 
The cost of an unintended pregnancy in a French minor is estimated to be 1630€ 
(1330€ - 1803€ ). Almost 4 million€ (3.1-13.7million€ ) could have been saved by using 
ulipristal acetate instead of levonorgestrel in 2010. The incremental cost of avoid-
